论文部分内容阅读
目的观察布地奈德雾化吸入预防肺炎支原体感染诱发儿童哮喘急性发作的临床疗效。方法将122例既往符合支气管哮喘诊断标准,入院时尚未出现喘息的肺炎支原体感染患儿随机分成治疗组60例,对照组62例。治疗组在接受一般治疗的基础上,予布地奈德混悬液1mg加生理盐水至3ml雾化吸入,1次/d,疗程3～5d。结果治疗组出现喘息、肺部哮鸣音的比例明显低于对照组,其有效率明显优于对照组,差异有统计学意义(P<0.01)。结论布地奈德雾化吸入能有效减少肺炎支原体感染诱发的儿童哮喘急性发作。
Objective To observe the clinical efficacy of budesonide inhalation to prevent the acute attack of childhood asthma caused by mycoplasma pneumoniae infection. Methods A total of 122 children with Mycoplasma pneumoniae pneumonia who did not appear wheezing on admission were randomly divided into treatment group (n = 60) and control group (n = 62). The treatment group received general treatment on the basis of budesonide suspension 1mg plus saline to 3ml inhalation, 1 / d, treatment of 3 ~ 5d. Results The treatment group wheezing, lung wheeze ratio was significantly lower than the control group, the effective rate was significantly better than the control group, the difference was statistically significant (P <0.01). Conclusion Budesonide inhalation can effectively reduce the acute episode of childhood asthma induced by Mycoplasma pneumoniae infection.